IFFIm widely recognised for innovation

As the first development finance entity in history to attract long-term, irrevocable and legally binding commitments from donors, IFFIm has built a strong reputation for innovation.

IFFIm's inaugural Uridashi bond included among the market's 25 most influential transactions by EuroWeek.

Cited as “SRI Innovation of the Decade” by mtn-i, the news / analytics provider.

IFFIm’s debut Sukuk was awarded Social Impact Deal of 2014 by Islamic Finance News.

Recognised for its role in investing in and aiding development by the Action Agenda of the Financing Development Conference in Addis Ababa, Ethiopia, in 2015. The Action Agenda, endorsed by representatives of the world’s governments, stated:
"...We encourage consideration of how existing mechanisms, such as the International Finance Facility for Immunisation, might be replicated to address broader development needs..."  

Financial Times/IFC

'Achievement in Transformational Finance Award' for IFFIm’s November 2014 sukuk.

48%

The weighted average price of pentavalent vaccine per dose dropped from US$ 2.98 in 2010 to US$ 1.55 in 2016, and is expected to decrease further to US$ 0.79 by 2019.

Gavi

More facts...

close icon

modal window here